NDAINJECTIONINJECTABLE
Approved
Jan 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
TRILAFON (perphenazine) by Merck & Co. is clinical pharmacology pharmacokinetics following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. Approved for schizophrenia, psychotic disorders. First approved in 1958.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRILAFON (perphenazine) is a first-generation antipsychotic administered via injection for schizophrenia and psychotic disorders. It works as a dopamine antagonist with a 9–12 hour half-life and reaches steady state within 72 hours. The drug undergoes extensive hepatic metabolism via CYP2D6, making it subject to genetic polymorphism affecting drug exposure.
LOE Approaching
As LOE approaches, the brand team is likely small and focused on defensive positioning; limited growth investment expected.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours. In a study in…
Indications (2)
Worked on TRILAFON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.